Replies to post #48101 on Univec Inc (UNVC)

[Toodles]

$UNVC: Reminder For New Lookers:

RewardStream Solutions Inc. Key Developments

RewardStream Solutions Inc. Announces Management Changes
Apr 26 19

RewardStream Solutions Inc. announced the appointment of Dr. David Dalton as a Director of the company, replacing Danilen Villanuevae who has resigned as a director of the company. The company is also announced that Geoff Balderson has been appointed Chief Financial Officer, replacing Usama Chaudhry. Currently Dr. Dalton is a director of AGRIMED. In addition to over 45 years' experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc. and Univec Inc. (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom.

Re­ward­stream to ac­quire EuroMed Ther­a­peu­tics
Mr. Pa­trick Mor­ris re­ports6 May 2019

RE­WARD­STREAM SOLUTIONS Inc. has en­tered into a let­ter of in­tent, dated ef­fec­tive April 30, 2019, pur­suant to which it pro­poses to ac­quire all of the out­stand­ing share cap­i­tal of EuroMed Ther­a­peu­tics Ltd. EuroMed is an arm’s-length company, es­tab­lished un­der the laws of the Province of Bri­tish Columbia, in­volved in the cul­ti­va­tion and ex­port­ing of med­i­cal-grade cannabis pro­duced in green­house fa­cil­i­ties lo­cated in Is­rael. EuroMed aims to be a lead­ing low-cost, high-qual­ity, med­i­cal-grade cannabis pro­ducer in Is­rael with a fo­cus on both the do­mes­tic Is­raeli mar­ket and the emerg­ing Euro­pean cannabis mar­ket.

EuroMed, through its wholly owned Is­raeli sub­sidiary, Euro­cann Agritech Ltd., owns a 74-per-cent eq­uity stake in a 269,098square-foot (25-dunam) cannabis des­ig­nated cul­ti­va­tion prop­erty lo­cated 45 min­utes out­side of Jerusalem, Is­rael. EuroMed in­teads to build a 22,000-square-foot green­house fa­cil­ity on the prop­erty to cul­ti­vate med­i­cal-grade cannabis for the pur­poses of ser­vic­ing the do­mes­tic med­i­cal cannabis mar­ket and ex­ports into Europe. EuroMed will be work­ing with lead­ing green­house en­gi­neer­ing and con­struc­tion firm Eisen­berg Agri company (Is­rael) Ltd. (EACi) to de­sign and build a state-of-the-art mod­u­lar green­house fa­cil­ity with ex­pected com­ple­tion by March, 2020.

In ac­cor­dance with the terms of the trans­ac­tion, the company pro­poses to con­sol­i­date its out­stand­ing share cap­i­tal on a one-for-two ba­sis, and is­sue 40 mil­lion post­share consolidation com­mon shares to the share­hold­ers of EuroMed in ex­change for all of the out­stand­ing share cap i tal of EuroMe d. Fol­loi­wng com­ple­tion of the share consolidation, and the is­suance of the con­sid­er­a­tion shares, the co m pany is ex­pected to have ap­prox­i­mately 48,741,562 com­mon shares out­stand­ing. At this time, the is­suance of the con­sid­er­a­tion shares to the share­hold­ers of EuroMed is not ex­pected to re­sult in the cre­ation of any new in­sid­ers or con­trol per­sons of the company.

Prior to clos­ing of the trans­ac­tion, the company in­tends to ap­ply to list its com­mon shares on the Cana­dian Se­cu­ri­ties Ex­change and vol­un­tar­ily delist its shares from the TSX Ven­ture Ex­change. On clos­ing of the trans­ac­tion, it is an­tic­i­pated that the company will change its name to EuroMed Ther­a­peu­tics Ltd., and will re­con­sti­tute its board and man­age­ment to con­sist of mem­bers mu­tu­ally agree­able to the company and EuroMed. In con­nec­tion with com­ple­tion of the trans­ac­tion, the company in­tends to un­der­take a non-bro­kered pri­vate place­ment of sub­scrip­tion re­ceipts to raise not less than $2.5-mil­lion. The company will pro­vide ad­di­tional in­for­ma­tion re­gard­ing the terms of the fi­nanc­ing as soon as it be­comes avail­able. In con­nec­tion with the trans­ac­tion, the company an­tic­i­pates is­su­ing four mil­lion post­share consolidation com mon shares to an arm’s-length third party who as­sisted in in­tro­duc­ing the trans­ac­tion to the company. All se­cu­ri­ties is­sued in con­nec­tion with the trans­ac­tion, and the fi­nanc­ing, will be sub­ject to a four-month-an­done-day statu­tory hold pe­riod.

Com­ple­tion of the trans­ac­tion re­mains sub­ject to a num­ber of con­di­tions, in­clud­ing the com­ple­tion of sat­is­fac­tory due dili­gence, the ne­go­ti­a­tion and fi­nal­iza­tion of de­fin­i­tive doc­u­men­ta­tion, re­ceipt of any re­quired reg­u­la­tory and third party con­sents, ap­proval of mi­nor­ity share­hold­ers of the company to the delist­ing of the company’s com­mon shares from the TSX Ven­ture Ex­change, com­ple­tion of the share consolidation, com­ple­tion of the fi­nanc­ing, the Cana­dian Se­cu­ri­ties Ex­change hav­ing con­di­tion­ally ac­cepted the listing of the company’s com­mon shares, the TSX Ven­ture Ex­change hav­ing con­sented to the vol­un­tar­ily delist­ing of the company’s com­mon shares, and the sat­is­fac­tion of other cus­tom­ary clos­ing con­di­tions. The trans­ac­tion can­not close un­til the re­quired ap­provals are ob­tained, and the company’s com­mon shares have been delisted from the TSX Ven­ture Ex­change. There can be no as­sur­ance that the trans­ac­tion will be com­pleted as pro­posed or at all, or that the company’s com­mon shares will be listed and posted for trad­ing on any stock ex­change. Trad­ing in the company’s com­mon shares is cur­rently sus­pended and it is an­tic­i­pated that trad­ing will re­main sus­pended un­til com­ple­tion of the trans­ac­tion.

Fur­ther in­for­ma­tion re­gard­ing the trans­ac­tion, in­clud­ing the terms of the fi­nanc­ing, a de­tailed use of pro­ceeds for the fi­nanc­ing, fi­nan­cial in­for­ma­tion of EuroMed, and de­tails re­gard­ing the pro­posed board and man­age­ment of the company fol­low­ing com­ple­tion of the trans­ac­tion will be made avail­able in due course. Read­ers are en­cour­aged to re­view the listing state­ment, which will be pre­pared by the company in con­nec­tion with the listing of the company on the Cana­dian Se­cu­ri­ties Ex­change, and which will be made avail­able un­der the company’s pro­file on SEDAR.

We seek Safe Har­bor.

Ge­of­frey Balder­son, David Dal­ton, Pa­trick Clarence Mor­ris

(REW) Shares: 17,483,081

https://www.pressreader.com/canada/stockwatch...5760128384

David Dalton as one of the “Top 100 Healthcare Leaders” for 2019. The award will be presented in June.

https://johnhopebryant.com/2019/05/dr-david-dalton-named-to-top-100-healthcare-leaders-list-for-2019.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+typepad%2Fjohnhopebryant%2Fjohn_hope_bryant_+%28John+Hope+Bryant+%3A+Leading+a+Silver+Rights+Movement%29

Talk about an unsung hero. Dr. David Dalton just may be one of the most impressive African-American business leaders that most have never heard of -- and I aim to change all of that. I want the world to know about my amazing, inspiring, brilliant and giving businessman and philanthropist father-in-law -- Dr. Dalton.

In addition to being a one of a kind role model father, husband, business leader and entrepreneur in the medical and healthcare fields, Dr. Dalton is just one incredible 'heart' of a human being. Below is his most recent national accomplishment, made public just this week:
The International Forum on Advancements in Healthcare (IFAH) has named Dr. David Dalton as one of the “Top 100 Healthcare Leaders” for 2019. The award will be presented in June.

$$$UNVC$$$